First Time Loading...

C4 Therapeutics Inc
NASDAQ:CCCC

Watchlist Manager
C4 Therapeutics Inc Logo
C4 Therapeutics Inc
NASDAQ:CCCC
Watchlist
Price: 6.74 USD 4.82% Market Closed
Updated: May 5, 2024
CCCC
/
Income Statement
/
Interest Income Expense

C4 Therapeutics Inc
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

C4 Therapeutics Inc
Interest Income Expense Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
C4 Therapeutics Inc
NASDAQ:CCCC
Interest Income Expense
$8.4m
CAGR 3-Years
N/A
CAGR 5-Years
65%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Interest Income Expense
-$1.8B
CAGR 3-Years
8%
CAGR 5-Years
-7%
CAGR 10-Years
-19%
Gilead Sciences Inc
NASDAQ:GILD
Interest Income Expense
-$757m
CAGR 3-Years
35%
CAGR 5-Years
0%
CAGR 10-Years
-10%
Amgen Inc
NASDAQ:AMGN
Interest Income Expense
-$2.6B
CAGR 3-Years
-38%
CAGR 5-Years
-27%
CAGR 10-Years
-16%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Interest Income Expense
$563.1m
CAGR 3-Years
78%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Interest Income Expense
$172.2m
CAGR 3-Years
7%
CAGR 5-Years
65%
CAGR 10-Years
N/A

See Also

What is C4 Therapeutics Inc's Interest Income Expense?
Interest Income Expense
8.4m USD

Based on the financial report for Dec 31, 2023, C4 Therapeutics Inc's Interest Income Expense amounts to 8.4m USD.

What is C4 Therapeutics Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
65%

Over the last year, the Interest Income Expense growth was 521%.

ALPHA SPREAD
Join more than 134,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.